NCT01435122 · REGISTRY CONDITION SEARCH

A Study of Axitinib in Advanced Carcinoid Tumors

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2018-10-02

The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing. Researchers also want to find out if Axitinib is safe and tolerable.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Rate of Progression Free Survival (PFS)

→

outcome · POSTED

Median Progression Free Survival

→

outcome · POSTED

Tumor Response Rate

→

outcome · POSTED

24 Month Overall Survival (OS) Rate

→

outcome · POSTED

Time to Treatment Failure

→

outcome · POSTED

Occurrence of Possibly Related Adverse Events (AEs)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Locally unresectable or metastatic well-and moderately-differentiated (low- or intermediate- grade) neuroendocrine tumors of the aerodigestive tract (e.g. foregut, midgut, and hindgut) and unknown primary site as well as rare primary sites (renal, ovarian, thymic, hepatic); Otherwise known as typical or atypical carcinoid tumors * Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) Criteria * Functional or nonfunctional tumors allowed * Evidence of progressive disease within 12 months of study entry * Adequate hepatic function: total bilirubin ≤1.5 x upper limit of normal (ULN)mg/dl; aspartic transaminase (AST) ≤2.5 x ULN (≤5 x ULN if attributable to liver metastases) * Adequate renal function: serum creatinine ≤ 1.5 x ULN * Adequate bone marrow function: absolute neutrophil count ≥ 1,500/mm³; platelets ≥75,000/mm³ * Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels ≤1.5 x ULN (unless patients receiving coumadin anticoagulation in which case a stable international normalization ration (INR) of 2-3 is required). * Urine protein \<2+proteinuria (or \<2 g proteinuria /24 hr) * Prior somatostatin-analog therapy required in patients with midgut carcinoid tumors * Minimum 4 weeks since completion of prior treatment (investigational or other). Prior treatment with chemotherapy, radiotherapy, hepatic artery embolization, surgery or other therapeutic agents is allowed. * Treatment related toxicity should have returned to baseline and/or ≤grade 1 prior to study treatment. * Prior or concurrent therapy with somatostatin analogs is permitted for the control of hormone-mediated symptoms, provided patient has been on a stable dose for at least 2 months and progressive disease on somatostatin analogs (SSTa) has been documented * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to treatment. * Ability to sign informed consent * Willingness and ability to comply with scheduled visits, laboratory tests and other study procedures Exclusion Criteria: * Poorly differentiated, high-grade (e.g. small cell or large cell) neuroendocrine carcinomas are excluded. * Pancreatic neuroendocrine tumors (NETs), paragangliomas, pheochromocytomas and medullary thyroid cancers are excluded. * Adenocarcinoid tumors and goblet cell carcinoid tumors are excluded. * Prior antiangiogenic therapy with a dedicated vascular endothelial growth factor (VEGF) pathway inhibitor * Clinically apparent central nervous system metastases * Any of the following within 12 months prior to study: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack * Deep venous thrombosis or pulmonary embolism within 6 months of study * Major surgery 4 weeks prior to enrollment * Inability to take oral medication or prior surgical procedures affecting absorption (including total gastric resection) * Active gastrointestinal bleeding, if transfusion dependent * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days * History of pulmonary hemorrhage or evidence of significant hemoptysis * History of serious non-healing wound, ulcer, or bone fracture within the past 28 days * Pre-existing thyroid abnormality allowed provided thyroid function can be controlled with medication. * Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors (i.e. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, clarithromycin, indinavir, saquinavir, ritonavir, nelfinavir, etc.) * Current use or anticipated need for treatment with drugs that are known inducers of CYP3AR or CYP1A2 (i.e carbamazepine, dexamethasone, omeprazole, phenobarbital, phenytoin, rifampin, St. John's Wart, etc.) * Uncontrolled serious medical or psychiatric illness. Patients with a "currently active" second malignancy other than non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer (staged pathological tumor-2 (pT2) with Gleason Score ≤ 6 and postoperative prostatic specific antigen (PSA) \< 0.5 ng/mL), or other adequately treated carcinoma-in-situ are ineligible. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥3 years. * Pregnant or lactating women, or adults of reproductive potential who are not using effective birth-control methods. * Prior antitumor therapy within 4 weeks of enrollment (with exception of somatostatin analogs) * Liver-directed therapy within 2 months of enrollment. Prior treatment with radiotherapy (including radio-labeled spheres and/or cyberknife, hepatic arterial embolization (with or without chemotherapy) or cryotherapy/ablation is allowed if these therapies did not affect the areas of measurable disease being used for this protocol or if progressive disease can be documented in the previously treated area. * Recent infection requiring systemic anti-infective treatment that was completed ≤14 days prior to enrollment (with the exception of uncomplicated urinary tract infection or upper respiratory tract infection) * Uncontrolled hypertension (blood-pressure \>140/90). Patient with baseline hypertension may be eligible after initiation of antihypertensive therapy.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
The investigational drug used in this study is axitinib, and is available as tablets. You will take the tablet orally with food. Doses should be taken around 12 hours apart continuously, without scheduled breaks. If you vomit anytime after taking a dose do not take another tablet to "make up the dose" but instead continue taking your next dose as planned. Any missed dose may be taken late (up to 3 hours before the next scheduled dose); otherwise it should be skipped. If doses are missed or vomited, please keep track of this and report at your next visit.
intervention Names
Drug: Axitinib
label
Axitinib Administration
type
EXPERIMENTAL

interventions

arm Group Labels
Axitinib Administration
description
Axitinib Administration as outlined in Arm description
name
Axitinib
other Names
AG013736
selective inhibitor of receptor tyrosine kinases
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 30
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Progression-free survival rate at 12 months. PFS: determined as the time from administration of the initial dose of axitinib until objective tumor progression using Response Evaluation Criteria In Solid Tumors (RECIST), or death. Progressive Disease (PD) Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. Stable Disease (SD): Neither sufficient shrinkage to qualify for Partial Response (PR) nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
measure
Rate of Progression Free Survival (PFS)
time Frame
12 Months
description
Post follow-up progression free survival at time of analysis.
measure
Median Progression Free Survival
time Frame
Up to 36 Months

secondary Outcomes

description
Tumor response rate using RECIST. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
measure
Tumor Response Rate
time Frame
12 Months
description
Overall survival by Kaplan Meier, determined from the time of drug administration to death from any cause. The effect of an intervention is assessed by measuring the number of subjects survived or saved after that intervention over a period of time. The time starting from a defined point to the occurrence of a given event, for example death is called as survival time and the analysis of group data as survival analysis.
measure
24 Month Overall Survival (OS) Rate
time Frame
24 months
description
Time to Treatment Failure: Time from administration of the initial dose of axitinib until study discontinuation for any reason (e.g., disease progression, toxicity, death, withdrawal of consent).
measure
Time to Treatment Failure
time Frame
12 Months
description
Grade 2 through 4 toxicities considered at least possibly related to treatment. Percentage of participants affected per category. Safety assessments will consist of monitoring and recording all adverse events and serious adverse events, the regular monitoring of hematology and blood chemistry parameters and regular physical examinations. Adverse events will be evaluated continuously throughout the study. Safety and tolerability will be assessed according to the National Institute of Health/National Cancer Institute (NIH/NCI) Common Terminology Criteria for Adverse Events version 4 (CTCAE v4) available at: http://ctep.cancer.gov/protocolDevelopment/electronic\_applications/ctc.htm.
measure
Occurrence of Possibly Related Adverse Events (AEs)
time Frame
12 Months

Full study description

brief Summary: The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing. Researchers also want to find out if Axitinib is safe and tolerable.
detailed Description: This is a bi-institutional, prospective phase II, open-label study. The target population is comprised of adult patients with histologically confirmed unresectable or metastatic carcinoid tumors. Carcinoid tumors are defined as well to moderately differentiated neuroendocrine tumors of the digestive tract and lungs. Patients with metastatic carcinoid tumors of unknown primary as well as rare primaries (renal, ovarian, thymic, hepatic) will also be eligible. Patients will be drawn from two institutions Moffitt Cancer Center (MCC) and The University of California, San Francisco (UCSF).

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-d47528c26b1fded9fee5
requested nct id
NCT01435122
primary nct id
NCT01435122
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Ovarian+Germ+Cell+Tumors&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
359ee71d54598877a70c4f96300e96532a9c096cf831e27a29687916b1e2237d
payload sha256
183ef15a273d2a47409a46ac14159eab776a5bdd00d85e1947aad9f6258e3a44
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-d47528c26b1fded9fee5
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01435122
occurrences
context exact
NCT01435122
end
11
exact text
NCT01435122
start
0
offset unit
unicode_code_points
query cond
Ovarian Germ Cell Tumors
query disease state id
ds-ovarian-germ-cell-tumors
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-ovarian-germ-cell-tumors-000.json
source file sha256
359ee71d54598877a70c4f96300e96532a9c096cf831e27a29687916b1e2237d
source json pointer
/studies/30/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
8380d20534f85503f10a21a7e99461a529dc1bb5482c173b175e5b88378da38b
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Ovarian+Germ+Cell+Tumors&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice